Short Interest in CSL Limited (OTCMKTS:CSLLY) Declines By 98.5%

CSL Limited (OTCMKTS:CSLLY) was the target of a large drop in short interest during the month of March. As of March 15th, there was short interest totalling 300 shares, a drop of 98.5% from the February 28th total of 20,000 shares. Based on an average trading volume of 134,500 shares, the days-to-cover ratio is presently 0.0 days. Currently, 0.0% of the shares of the company are short sold.

Analyst Upgrades and Downgrades

Separately, The Goldman Sachs Group raised CSL to a “strong-buy” rating in a report on Thursday, January 16th.

CSL Stock Down 2.8 %

OTCMKTS CSLLY traded down $2.29 during trading hours on Thursday, reaching $79.17. The company’s stock had a trading volume of 48,223 shares, compared to its average volume of 88,004. CSL has a 1 year low of $77.37 and a 1 year high of $109.00. The firm’s 50-day moving average price is $82.58 and its 200-day moving average price is $89.83. The company has a quick ratio of 0.97, a current ratio of 2.18 and a debt-to-equity ratio of 0.58.

About CSL

CSL Limited researches, develops, manufactures, markets, and distributes biopharmaceutical and vaccines in Australia, the United States, Germany, the United Kingdom, Switzerland, China, Hong Kong, and internationally. The company operates through CSL Behring, CSL Seqirus, and CSL Vifor segments. The CSL Behring segment offers plasma products, gene therapies, and recombinants.